Freshly elutriated human monocytes were allowed to interact with an anti-ICAM3-coated well, which leads to rapid PPAR␥ expression (13), and then stimulated, or not (negative, oxLDL), with oleoyl LPA. Some cells were then briefly exposed to oxidized LDL before intracellular lipid stores were visualized with oil red O stain. (b) LPA increases the expression of CD36 on the surface of primary human monocytes. Monocytes engaging anti-ICAM3 were treated or not with LPA, and then recovered by gentle scraping and washing by centrifugation before their surface CD36 was assessed by flow cytometry. (c) LPA and the LPA analogs XY4 and XY8 stimulate CD36 promoter function only when the PPRE is present. RAW264.7 cells were transfected with the human CD36 promoter containing the PPRE (CD36 Ϫ273 ) or a reporter that lacks only this element (CD36 Ϫ261 ) and then stimulated with oleoyl LPA, azPC, XY4, or XY8. Expression of luciferase normalized to ␤-galactosidase was determined as above. (d) Anti-CD36 blocks LPA-stimulated accumulation of cholesterol from oxidized LDL. Freshly isolated human monocytes were treated as in a, but after being preincubated with a blocking anti-CD36 antibody before exposure to oxidized LDL.
Epidermal growth factor receptor (EGFR) has attracted considerable attention as a target for cancer therapy. Wild-type (wt)EGFR is amplified͞overexpressed in a number of tumor types, and several mutant forms of the coding gene have been found, with ⌬EGFR, a deletion mutation lacking exons 2-7 of the external domain, being the most common and particularly associated with glioblastoma. We generated monoclonal antibodies (mAbs) against NR6⌬EGFR (mouse fibroblast line NR6 transfected with ⌬EGFR). mAb 806 with selective reactivity for NR6⌬EGFR in mixed hemadsorption assays, fluorescenceactivated cell sorting, Western blot, and immunohistochemistry was analyzed in detail and compared with mAbs 528 (anti-wtEGFR) and DH8.3 (anti-⌬EGFR). In xenograft tumors and molecularly pretyped glioblastomas, the reactivity pattern was as follows: 528 reactive with amplified and nonamplified wtEGFR; DH8.3 reactive with ⌬EGFR; and 806 reactive with amplified͞overexpressed wtEGFR (with or without ⌬EGFR). In normal tissues, 528 but not DH8.3 or 806 was widely reactive with many organs, e.g., liver expressing high EGFR levels. In glioblastoma and non-CNS tumor panels, 806 was reactive with a high proportion of glioblastomas and a substantial number of epithelial cancers of lung and of head and neck. DH8.3 reactivity was restricted to ⌬EGFR-positive glioblastoma. Thus, 806 represents a category of mAbs that recognizes tumors with EGFR amplification͞overexpres-sion but not normal tissues or tumors with normal EGFR levels. Our study also indicates that ⌬EGFR is restricted to glioblastoma, in contrast to other reports that this mutation is found in tumors outside the brain. G rowth factor receptors are promising targets for antibodybased cancer therapies. Because of their cell-surface location, they are readily accessible, and therapeutic antibodies can exert their inhibitory effects by either interfering with cellular signaling or targeting toxic molecules or biological effectors to the tumor site (1) .
The epidermal growth factor receptor (EGFR) is expressed in normal tissues and neoplastic lesions of most organs, and its expression level has been associated with biological characteristics of tumors (2) . Elevated levels of EGFR have been demonstrated in many different types of cancer including glioblastoma, and EGFR overexpression seems to be associated with poor prognosis in several neoplasms (3) . EGFR overexpression is often associated with gene amplification (4) (5) (6) (7) (8) . In glioblastoma, EGFR amplification has been shown to be accompanied by gene rearrangement (9) (10) (11) , frequently with deletions in the coding region. Several mutant forms have been found (12, 13) , and among these the most common mutation is the ⌬2-7 deletion (⌬EGFR), which lacks exons 2-7 of the external EGFR domain, resulting in the loss of an 801-bp fragment of the wild-type (wt) gene (14) . Several studies have indicated that the presence of ⌬EGFR enhances the tumorigenic behavior of cancer cells (15) (16) (17) . ⌬EGFR has only been found in neoplastic lesions and not in any normal tissue. Its tumor-restricted expression and cell-surface location make ⌬EGFR a potentially ideal target for immunotherapeutic strategies.
Antibody targeting of EGFR is currently being pursued as a promising approach to treating cancers at various sites (18) . Although a wide variety of antibodies to the wtEGFR are available (19, 20) , only a few reagents to its mutant form have been generated (11, (21) (22) (23) . Some of the currently available anti-⌬EGFR reagents are polyclonal antibodies (11, 21, 22) , but these are not useful for therapeutic applications. Also, most ⌬EGFR reagents have been tested on only a limited number of tissues (22, (24) (25) (26) (27) , and no comprehensive analysis of ⌬EGFR expression in normal and tumor tissue has been performed.
The present study describes the generation and characterization of 806, a murine antibody raised against cells transfected with ⌬EGFR. The reactivity of 806 was compared with 528, an antibody to wtEGFR (28) , and DH8.3, an antibody raised against ⌬EGFR (21) . 806 has unique features that differentiate it from other EGFR-related mAbs, namely its ability to distinguish cells with an amplified͞overexpressed EGFR phenotype from cells having wt levels of EGFR expression.
Materials and Methods
Cell Lines. For immunization and specificity analyses, a panel of cell lines, parental or transfected with either the human wtEGFR gene or the ⌬EGFR gene carrying the ⌬2-7 deletion mutation, were used: murine fibroblast cell line NR6, NR6 ⌬EGFR , NR6 wtEGFR , human glioblastoma cell line U87MG (expressing low levels of endogenous wtEGFR), U87MG wtEGFR , U87MG ⌬EGFR , and human squamous cell carcinoma cell line A431 (expressing high levels of wtEGFR) (29) . Cell lines and transfections have been described (15) .
Generation of mAbs.
The murine fibroblast line NR6 ⌬EGFR was used as immunogen. Mouse hybridomas were generated by immunizing BALB͞c mice five times s.c. at 2-to 3-week intervals with 5 ϫ 10 5 to 2 ϫ 10 6 cells in Freund's adjuvant. Complete Freund's adjuvant (Difco) was used for the first injection, and incomplete Freund's adjuvant (Difco) was used for subsequent injections. Spleen cells from immunized mice were fused with mouse myeloma cell line SP2͞0.
Supernatants from newly generated clones were screened in mixed hemadsorption assays for reactivity with cell lines NR6, NR6 wtEGFR , and NR6 ⌬EGFR. Supernatants with specificity for NR6 ⌬EGFR were then tested on the human glioblastoma cell lines U87MG, U87 wtEGFR , and U87 ⌬EGFR . Supernatants continuing to show selective reactivity with ⌬EGFR-transfected cells were tested by fluorescence-activated cell sorting, Western blots, and immunohistochemistry.
Two additional mAbs were included in our study: 528, with specificity for wtEGFR (28) , and DH8.3, generated against a synthetic peptide spanning the junctional sequence of the ⌬2-7 EGFR deletion mutation (21) .
Mixed Hemadsorption Assay. The hemadsorption assay, which detects surface-bound IgG by adherence of rabbit anti-mouse IgGcoated human red blood cells (blood group O) to target cells, was performed as described (30) .
Western Blots. Triton X-100 (0.3% in PBS, pH 7.5) lysates of cultured cells were resolved by SDS͞PAGE 6% polyacrylamide Tris-glycine precast gels (NOVEX, San Diego) under reducing (5% ␤-mercaptoethanol) conditions. Proteins were blotted to poly-(vinylidene difluoride) (Immobilon-P, Millipore) and incubated with hybridoma supernatant diluted 1:10 or protein A affinitypurified mAbs (5 g͞ml). Specific binding was detected by alkaline phosphatase-conjugated species-specific secondary antibody and visualized by using chemiluminescent detection (Tropix, Bedford, MA). Blocking and washing steps were carried out per manufacturer instructions.
Molecular Typing. The gene analysis was done as described (6, 9) . The presence of EGFR gene amplification and gene rearrangement was determined by PCR and hybridization of a cDNA probe to Southern blots (6) . Amplification was quantitated by comparison with patient blood DNA. The consequences of rearrangements for the EGFR transcript were determined by RT-PCR.
Immunohistochemistry. All analyses were performed on frozen tissues. Tissues were embedded in OCT compound (TissueTek, Torrance, CA) and snap-frozen in isopentane precooled in dry ice. Five-micrometer sections were applied to slides (Superfrost, Fisher) and fixed for 10 min in cold acetone (4°C). Primary antibodies were detected with a biotinylated horse anti-mouse antibody (Vector Laboratories) followed by an avidin-biotincomplex reaction (ABC Elite, Vector Laboratories). Diaminobenzidine tetrahydrochloride (BioGenex Laboratories, San Ramon, CA) was used as chromogen. As an alternative for the avidinbiotin-complex method, streptavidin-alkaline-phosphatase (SA, Roche Molecular Biochemicals) followed by new fuchsin chromogen (BioGenex Laboratories) was used. With the xenografted tumors, a preincubation with unlabelled secondary anti-mouse reagent was done in preliminary assays to block the reactivity of endogenous mouse Igs. However, this preincubation did not improve the staining, because endogenous immunoreactivity did not interfere with the interpretation of the immunohistochemical staining. The blocking step therefore was finally omitted.
The number of stained cells was estimated and graded as follows: ''focal,'' Ͻ5%; ''ϩ,'' Ͼ5-25%; ''ϩϩ,'' Ͼ25-50%; ''ϩϩϩ,'' Ͼ50-75%; and ''ϩϩϩϩ,'' Ͼ75%.
Tissues. The reactivity of the mAbs in immunohistochemistry was assessed first on a small panel of xenografted tumors. U87MG, U87MG ⌬EGFR , and A431 cells were inoculated s.c. in the right thigh of nu͞nu mice (5 ϫ 10 5 to 2 ϫ 10 6 cells per mouse) and grown until a tumor diameter of Ϸ10 mm was reached.
Human tissues were provided by the tissue-procurement service of Memorial Sloan-Kettering Cancer Center and the Institute of Pathology of the Karolinska Hospital (Stockholm). For the initial immunohistochemical specificity analysis, a series of 17 glioblastomas was used. These tissues were preselected on the basis of a molecular pretyping for the presence of wtEGFR, ⌬EGFR, and EGFR amplification. In addition, three large frozen tissue panels were analyzed for reactivity with 806, 527, and DH8.3. These panels were (i) a set of normal tissues, (ii) a set of extracranial malignant neoplasms, and (iii) a series of 46 unselected glioblastomas. The glioblastomas were subsequently analyzed (as described above) for the presence of wtEGFR, EGFR mutations, and EGFR amplification.
Results
Selection of EGFR mAbs. Hybridomas were established from mice immunized with NR6 ⌬EGFR , and three clones, 124 (IgG2a), 806 (IgG2b), and 1133 (IgG2a), were initially selected for further characterization based on high titer of supernatants with NR6 ⌬EGFR and background reactivity with parental NR6 and NR6 wtEGFR cells in the hemadsorption assay (Fig. 5 , which is published as supporting information on the PNAS web site, www.pnas.org). These antibodies showed no reactivity (undiluted supernatant Յ10%) with the parental human glioblastoma cell line U87MG or U87MG wtEGFR but were strongly reactive with U87MG ⌬EGFR and to a lesser degree with A431. In fluorescence-activated cell-sorter analysis (data not included), 806 was unreactive with U87MG and intensively stained U87MG ⌬EGFR but showed some low-level reactivity with U87MG wtEGFR . In Western blot assays, 124, 806, and 1133 were tested with detergent lysates from NR6, NR6 ⌬EGFR , NR6 wtEGFR , U87MG, U87MG ⌬EGFR , U87MG wtEGFR , and A431. All three mAbs showed a similar reactivity pattern, detecting both wtEGFR (170 or 160 kDa in case of A431 cells) and ⌬EGFR (140 kDa), whereas DH8.3 (reference antibody for ⌬EGFR) reacted only with the characteristic 140-kDa ⌬EGFR band (Fig. 6 , which is published as supporting information on the PNAS web site).
Tumor Xenografts. Table 1 and Fig. 1 show the results of immunohistochemical analysis with 124, 806, and 1133, as well as 528 and DH8.3, on xenografts of U87MG, U87MG ⌬EGFR , and A431. All mAbs showed strong staining of U87MG ⌬EGFR xenografts. Only 528 stained the parental U87MG xenograft. In xenografts of squamous cell carcinoma A431, 528 showed strong homogeneous staining, whereas 124, 806, and 1133 reacted primarily with basally located cells and did not react with the upper keratinizing cell layers. DH8.3 did not stain the A431 xenograft. Because of low background reactivity, 806 was selected for all subsequent analysis.
Pretyped Glioblastomas. The immunohistochemical staining of glioblastomas pretyped for wtEGFR, ⌬EGFR, and EGFR amplification is shown in Table 2 and Fig. 2 . These tissues showed more or less extensive cracking and spacing artifacts. This is a common phenomenon with frozen glioblastoma specimens, caused by the perifocal edema typically present in this type of tumor. Whereas 528 showed intense reactivity in most tumors, DH8.3 immunostaining was present solely in tumors expressing ⌬EGFR. 806 stained tumors with ⌬EGFR but also tumors with EGFR amplification without ⌬EGFR. No or weak 806 reactivity was present in tumors without EGFR amplification. Minor stromal staining is due to detection of endogenous mouse antibodies. Foc., focal.
Normal Tissue Panel. The results of immunohistochemical staining of normal tissues are shown in Fig. 3 and Table 6 (which is published as supporting information on the PNAS web site). 528 showed immunoreactivity in all normal tissues tested. The 528-reactivity pattern is not described in detail here, because the distribution of EGFR in normal tissues has been reported in detail (31, 32) . No normal tissue showed significant 806 staining. Some inconsistent focal staining was present in basal cells of one of five samples of normal skin and in the squamous epithelium in one of five samples of tonsil mucosa. This staining was not present in the other four samples and was variable within the single positive tissues. In placenta, occasional staining of the trophoblast epithelium was observed. This low-level reactivity of 806 with skin and placenta might be expected, because both keratinocytes and trophoblastic epithelia are known to express high levels of EGFR (33). DH8.3 For the analysis in this table, a three-tier grading system (ϩ-ϩϩϩ) was used to indicate the number of stained cells.
Fig. 2. Hematoxylin͞eosin (A-C) and immunohistochemical (D-L) (avidinbiotin-complex technique, diaminobenzidine tetrahydrochloride chromogen) staining of three glioblastoma specimens pretyped for presence of wtEGFR (A, D, G, and J), amplified EGFR (B, E, H, and K), or amplified EGFR and ⌬EGFR (C, F, I, and L) with 528 (D-F), 806 (G-I), or DH8.3 (J-L). 528 staining of the three glioblastomas (D-F), 806 staining of glioblastoma having EGFR amplification without ⌬EGFR (H) or with ⌬EGFR (I), and DH8.3 staining of glioblastoma with amplified EGFR and ⌬EGFR (L) are shown.
showed virtually no staining of normal tissues with the exception of faint focal stromal staining in several tissues, which was considered nonspecific. Liver, an organ with high expression of EGFR, was negative for 806 and DH8.3.
Tumor Panel. Table 3 and Fig. 3 G-O show the results of immunostaining of the tumor panel. 528 gave intense and often homogeneous staining in a wide variety of different tumor types. Immunoreactivity was present in the tumoral as well as the stromal components of epithelial neoplasms and sarcomas. Only melanomas and seminomas revealed a generally weak staining pattern. The reactivity pattern of 528 in tumors is not specified further, because it has been analyzed in several studies (34) (35) (36) (37) . 806 showed positive staining in carcinomas of head and neck, esophagus, lung, and urinary bladder. These 806-positive tumors were mostly squamous cell carcinomas or tumors with varying degrees of squamous cell differentiation. In non-small-cell lung carcinomas, 17 of 26 squamous cell carcinomas were 806-positive, whereas large-cell carcinomas and adenocarcinomas were less immunoreactive. Of the 17 positive cases, 11 showed homogeneous 806 staining, i.e., immunoreactivity in Ͼ50% of the tumor cells. In metastatic head and neck squamous cell carcinoma, 10 of 10 cases were positive for 806, with 4 cases showing homogeneous staining. In esophageal squamous cell carcinoma, 7 of 10 were positive, and 5 of the 7 positive cases showed homogeneous staining. In tumors of the urinary bladder, those with squamous differentiation and occasionally those with urothelial differentiation were reactive with 806. Little 806 staining was observed in other tumor types. mAb DH8.3 showed no immunoreactivity in this tumor panel, indicating no or little expression of ⌬EGFR in extracranial neoplasms. For instance, cancers of breast and ovary, tumors reported to have ⌬EGFR (24, 26), were negative. There was some inconsistent focal endothelial staining of blood vessels and a varying weak diffuse staining of connective tissue, which was observed previously in normal tissues. The latter staining was restricted to small areas and also strongly depended on the concentration of antibody and was finally regarded as nonspecific background reactivity. Importantly, no convincing reactivity in tumor cells was seen.
Unselected Glioblastomas. Tables 4 and 5 summarize the results of immunostaining of 46 unselected glioblastomas. 528 showed strong reactivity with all but two tumors, and in most cases there was a predominantly homogeneous staining (Fig. 4) . 806 was reactive with 27 of 46 (58.7%) glioblastomas, with 22 of the positive cases showing staining of Ͼ50% of the tumor cells (ϩϩϩ-ϩϩϩϩ corresponding to our grading system). DH8.3 stained 15 of 46 (32.6%) glioblastomas, 9 of which showed immunostaining in Ͼ50% (ϩϩϩ-ϩϩϩϩ) of the tumor cells (Fig. 4) .
We next compared 806 and DH8.3 reactivity with the presence or absence of EGFR amplification and ⌬EGFR. In the 44 cases tested for EGFR amplification, 30 cases cotyped with 806, i.e., 16 806-negative cases had no EGFR amplification, and 14 806-positive cases had EGFR amplification. However, 13 cases with 806 reactivity were negative for EGFR amplification, whereas 1 EGFRamplified case was 806-negative (case 35).
In the 41 cases typed for ⌬EGFR by RT-PCR, 34 cases cotyped with DH8.3: 12 cases were positive in RT-PCR and immunohistochemistry, and 22 cases were negative in both assays. Six cases showed discrepant results. Three of these (cases 2, 34, and 40) were DH8.3-positive͞⌬EGFR-negative, and three others (cases 12, 18, and 39) were DH8.3-negative͞⌬EGFR-positive. Case 3 (DH8.3-negative) revealed a mutation in the EGFR gene, but this was distinct from the classical ⌬2-7 deletion. As expected, 806 stained all DH8.3-positive tumors with the exception of one (case 35) (Fig. 4) .
Discussion
Antibody-based immunotherapy of tumors has experienced renewed interest based on the success of targeting the CD20 antigen of B cell lymphomas (38) and two members of the EGFR family, namely EGFR and HER-2neu (39, 40) . Several clinical studies using EGFR antibodies have been conducted and reveal promising results, especially when combined with additional treatment modalities such as radiation or chemotherapy (39) . However, EGFR is a normal constituent of many cell types, and organs such as liver and skin express high levels of EGFR, factors that complicate clinical use of antibodies to the wt receptor (2, 31, 41) . In fact, skin toxicity is commonly seen in patients treated with anti-EGFR antibodies (42) . For this reason, antibodies that target mutant EGFR, such as ⌬EGFR, or otherwise altered forms of EGFR would be highly desirable. The present study was prompted by the availability of a panel of mouse (NR6 fibroblast) and human (U87MG glioblastoma) cell lines transfected with wtEGFR or ⌬EGFR. The intention was to develop antibodies with specificity for ⌬EGFR, using the ⌬EGFR-transfected NR6 cell line as immunogen, and screening for antibodies that have selective cell-surface reactivity with ⌬EGFR-transfected NR6 and U87MG cells. We considered this an attractive alternative strategy to the one used to develop previous antibodies to ⌬EGFR, i.e., immunization with the peptide spanning the EGFR deletion mutation (21, 22) . To our surprise, the antibodies we isolated, such as 806, had specificity for cells with amplified EGFR expression regardless of the presence or absence of ⌬EGFR and did not react with cells expressing normal levels of EGFR. This reactivity pattern distinguishes 806 from antibodies to wtEGFR such as 225 and 528 (34, 41, 43, 44) and antibodies to ⌬EGFR such as DH8.3 (21) . In normal tissues, 528 stained a broad range of cell types in virtually every organ in the body, whereas DH8.3 showed no reactivity with any normal cell type. The normal tissue reactivity of 806 was also extremely limited, with the only exception being the occasional staining of basal cells in skin epithelium (a cell type known to have high levels of EGFR expression) in one of five specimens tested and the corresponding cell type in the mucosal epithelium of the tonsil in one of five specimens. Most importantly, 806 showed no reactivity with normal liver. The reactivity of 528, DH8.3, and 806 with the tumor panel also revealed clear distinctions among these antibodies. As with normal tissues, 528 reacted broadly with different tumor types as well as the normal tissue constituents of tumors. In contrast, DH8.3 reactivity was restricted to a subset of glioblastoma, and in 34 of 41 glioblastomas tested for both DH8.3 and ⌬EGFR, there was a clear correlation between immunostaining and presence of the mutation. In contrast to reports that non-small-cell lung cancer (26) , breast cancer (24, 27) , and ovarian cancer (24) show a high frequency of ⌬EGFR as detected by mAbs or polyclonal antibodies, we found no evidence for DH8.3 immunoreactivity with tumors outside the CNS. The serologic reagents used in these other studies have not been subjected to a comprehensive specificity analysis, and the discrepancies between our results and the previous reports may have to do with undefined cross-reactivities. However, a recent study reporting a high frequency of ⌬EGFR in invasive breast cancer indicates that the issue of ⌬EGFR in non-CNS awaits further study (27) .
In relation to DH8.3, 806 reacts with a higher percentage of glioblastomas than DH8.3 (58.7% vs. 32.6%) and also with tumor types known to have EGFR overexpression, e.g. cancers of the head and neck, lung, and bladder. Although 806 reactivity clearly correlated with EGFR amplification in glioblastoma, e.g. 14 of 15 glioblastomas with EGFR amplification were 806-positive, there were 13 glioblastomas that were 806-positive without having amplified EGFR expression. Because overexpression of EGFR in the absence of gene amplification occurs in a variety of tumors, e.g. breast, colorectum, and bladder (2, 3, 6) , it is likely that 806-positive͞EGFR amplification-negative glioblastomas have an EGFR overexpression phenotype. However, because many tumor types with reported EGFR overexpression, e.g. breast, showed little or no 806 staining, it seems likely that only a subset of EGFR overexpressing tumors, perhaps those exceeding a certain expression level, shows 806 reactivity.
The epitope recognized by 806 is currently unknown. 806 does not react with the junction peptide characteristic of the ⌬EGFR deletion mutation, clearly distinguishing 806 from antibodies detecting the ⌬EGFR mutation (unpublished data). The preferential reactivity of 806 with cells having high EGFR expression could be explained on the basis of affinity, i.e., 806 has a lower affinity than 528 for wtEGFR. Scatchard analysis of 806 and titration experiments with 806 and 528 do not lend support to this idea (45) (46) (47) . Our current hypothesis is that the EGFR expressed by cells with amplification or overexpression has an altered configuration or composition, e.g., aberrant glycosylation, and that 806 recognizes this altered state independent of the ⌬EGFR mutation. We have found recently that only a fraction of the EGFRs in overexpressing cells seems to have the 806 epitope; only 10% of the EGFRs from the A431 cell lines is immunoprecipitated by 806 (45) (46) (47) .
In summary, 806 represents a way to target cancer cells with EGFR amplification͞overexpression. Because of the higher frequency of glioblastoma with 806 reactivity than with antibodies detecting ⌬EGFR, and the substantial number of head and neck, lung, and bladder cancers that show 806 reactivity, therapeutic strategies based on 806-targeting offer attractive opportunities. The antitumor activity of 806 in mouse systems, including a model of human brain cancer (47) , provides encouragement for the clinical application of 806.
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